{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:56:43Z","timestamp":1792803403147,"version":"4.5.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.radonc.2023.109544","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:22:10Z","timestamp":1676895730000},"page":"109544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer"],"prefix":"10.1016","volume":"183","author":[{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Hinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Cozzarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Maingon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109544_b0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109544_b0010","first-page":"360","article-title":"Duration of androgen suppression in the treatment of prostate cancer","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109544_b0015","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92\u201302","volume":"21","author":"Hanks","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0020","first-page":"365","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109544_b0025","doi-asserted-by":"crossref","unstructured":"Roach M 3RD, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000;47:617-27. doi: 10.1016\/s0360-3016(00)00577-0. PubMed PMID: 10837944","DOI":"10.1016\/S0360-3016(00)00577-0"},{"key":"10.1016\/j.radonc.2023.109544_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the nrg oncology rtog 0126 randomized clinical trial","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol\u2022 Biol\u2022 Phys"},{"key":"10.1016\/j.radonc.2023.109544_b0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial","volume":"13","author":"Dearnaley","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0050","doi-asserted-by":"crossref","unstructured":"Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. The Lancet Oncology.17:464-74. doi: 10.1016\/S1470-2045(15)00567-7.","DOI":"10.1016\/S1470-2045(15)00567-7"},{"key":"10.1016\/j.radonc.2023.109544_b0055","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0060","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0065","doi-asserted-by":"crossref","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet. 2019;394:385-95. doi: https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6.","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"10.1016\/j.radonc.2023.109544_b0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2009.08.042","article-title":"IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy","volume":"93","author":"Alongi","year":"2009","journal-title":"Radiother Oncol: J Eur Soc Therap Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.radonc.2009.08.011","article-title":"Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer","volume":"93","author":"Wolff","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0080","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2023.109544_b0085","doi-asserted-by":"crossref","first-page":"e196562","DOI":"10.1001\/jamanetworkopen.2019.6562","volume":"2","author":"Jayadevappa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2023.109544_b0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JOP.18.00178","article-title":"Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer","volume":"14","author":"Gupta","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.radonc.2023.109544_b0095","doi-asserted-by":"crossref","unstructured":"Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. New England Journal of Medicine. 2017;376:417-28. doi: doi:10.1056\/NEJMoa1607529. PubMed PMID: 28146658.","DOI":"10.1056\/NEJMoa1607529"},{"key":"10.1016\/j.radonc.2023.109544_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0105","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109544_b0110","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.juro.2006.03.098","article-title":"Use of hormonal therapy in men with metastatic prostate cancer","volume":"176","author":"Lu-Yao","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0115","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/annonc\/mds618","article-title":"Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications","volume":"24","author":"Kuykendal","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.eururo.2016.02.057","article-title":"Assessment of the rate of adherence to international guidelines for androgen deprivation therapy with external-beam radiation therapy: a population-based study","volume":"70","author":"Dell\u2019Oglio","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0125","doi-asserted-by":"crossref","unstructured":"D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-74. doi: joc80111 [pii]. PubMed PMID: 9749478.","DOI":"10.1001\/jama.280.11.969"},{"key":"10.1016\/j.radonc.2023.109544_b0130","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0135","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0140","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2014.58.0662","article-title":"Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910","volume":"33","author":"Pisansky","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0145","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0150","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2021.07.039","article-title":"Dose escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG oncology\/RTOG 0815 randomized trial","volume":"111","author":"Krauss","year":"2021","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.109544_b0155","doi-asserted-by":"crossref","unstructured":"Malone S, Roy S, Eapen L, E C, MacRae R, Perry G, et al. Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial. Journal of Clinical Oncology. 2019:JCO.19.01904. doi: 10.1200\/JCO.19.01904.","DOI":"10.1200\/JCO.19.01904"},{"key":"10.1016\/j.radonc.2023.109544_b0160","doi-asserted-by":"crossref","unstructured":"Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, et al. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. Journal of Clinical Oncology. 2020:JCO.20.02438. doi: 10.1200\/JCO.20.02438.","DOI":"10.1200\/JCO.20.02438"},{"key":"10.1016\/j.radonc.2023.109544_b0165","doi-asserted-by":"crossref","unstructured":"Ma TM, Sun Y, Malone S, Roach M, Dearnaley D, Pisansky TM, et al. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. J Clin Oncol. 2022:JCO2200970. Epub 20221021. doi: 10.1200\/JCO.22.00970. PubMed PMID: 36269935.","DOI":"10.1016\/j.ijrobp.2022.07.459"},{"key":"10.1016\/j.radonc.2023.109544_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92\u201302: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0180","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.109544_b0185","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109544_b0190","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0195","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","article-title":"Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial","volume":"106","author":"de Vries","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109544_b0205","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0210","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.24392","article-title":"Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?","volume":"115","author":"Bria","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.109544_b0215","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review","volume":"77","author":"Moris","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0225","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109544_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2006.03.092","article-title":"Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone","volume":"176","author":"Granfors","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0235","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0240","doi-asserted-by":"crossref","unstructured":"Chun Chieh Lin PJG, Ahmedin Jemal, Jason A. Efstathiou. Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. J Natl Cancer Inst. 2015;107: djv119. doi: 10.1093\/jnci\/djv119.","DOI":"10.1093\/jnci\/djv119"},{"key":"10.1016\/j.radonc.2023.109544_b0245","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109544_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109544_b0260","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0265","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0270","doi-asserted-by":"crossref","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-555. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472-9. Epub 2006\/06\/06. doi: 10.1016\/s1470-2045(06)70700-8. PubMed PMID: 16750497.","DOI":"10.1016\/S1470-2045(06)70700-8"},{"key":"10.1016\/j.radonc.2023.109544_b0275","unstructured":"XXX"},{"key":"10.1016\/j.radonc.2023.109544_b0280","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer","volume":"32","author":"Abdollah","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0285","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/cncr.30373","article-title":"The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer","volume":"123","author":"Jegadeesh","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.109544_b0290","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2011.02.024","article-title":"Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis","volume":"59","author":"Briganti","year":"2011","journal-title":"Eur Urol."},{"key":"10.1016\/j.radonc.2023.109544_b0295","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2018.04.017","article-title":"Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection","volume":"74","author":"Abdollah","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0300","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bju.14241","article-title":"Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit","volume":"123","author":"Gupta","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2023.109544_b0305","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijrobp.2014.09.039","article-title":"Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96\u201302 trial","volume":"91","author":"Wiegel","year":"2015","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.109544_b0310","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","article-title":"Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes","volume":"76","author":"Preisser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0315","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijrobp.2008.11.007","article-title":"Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and\/or positive surgical margins","volume":"75","author":"Choo","year":"2009","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.109544_b0320","doi-asserted-by":"crossref","unstructured":"Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). The Lancet.380:2018-27. doi: http:\/\/dx.doi.org\/10.1016\/S0140-6736(12)61253-7.","DOI":"10.1016\/S0140-6736(12)61253-7"},{"key":"10.1016\/j.radonc.2023.109544_b0325","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0330","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)63946-8","article-title":"Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer","volume":"169","author":"Han","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0335","doi-asserted-by":"crossref","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75:967-87. Epub 2018\/10\/22. doi: 10.1016\/j.eururo.2018.10.011. PubMed PMID: 30342843.","DOI":"10.1016\/j.eururo.2019.03.027"},{"key":"10.1016\/j.radonc.2023.109544_b0340","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer","volume":"34","author":"Stish","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2013.08.013","article-title":"Early salvage radiotherapy following radical prostatectomy","volume":"65","author":"Pfister","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0350","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0355","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.radonc.2015.10.028","article-title":"The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival","volume":"118","author":"Bartkowiak","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0360","doi-asserted-by":"crossref","unstructured":"Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59:893-9. Epub 2011\/03\/11. doi: 10.1016\/j.eururo.2011.02.026. PubMed PMID: 21388736.","DOI":"10.1016\/j.eururo.2011.02.026"},{"key":"10.1016\/j.radonc.2023.109544_b0365","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0370","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2017.06.027","article-title":"A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer","volume":"73","author":"Spratt","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0375","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JU.0000000000000071","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO and AUA evidence-based guideline","volume":"201","author":"Morgan Scott","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109544_b0380","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0385","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.109544_b0390","doi-asserted-by":"crossref","unstructured":"van Dams R, Jiang NY, Fuller DB, Loblaw A, Jiang T, Katz AJ, et al. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. Int J Radiat Oncol Biol Phys. 2021;110:731-7. Epub 20210123. doi: 10.1016\/j.ijrobp.2021.01.016. PubMed PMID: 33493615; PubMed Central PMCID: PMC8956505.","DOI":"10.1016\/j.ijrobp.2021.01.016"},{"key":"10.1016\/j.radonc.2023.109544_b0395","doi-asserted-by":"crossref","unstructured":"Mahase SS, D'Angelo D, Kang J, Hu JC, Barbieri CE, Nagar H. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. JAMA Netw Open. 2020;3:e1920471. Epub 20200205. doi: 10.1001\/jamanetworkopen.2019.20471. PubMed PMID: 32022878.","DOI":"10.1001\/jamanetworkopen.2019.20471"},{"key":"10.1016\/j.radonc.2023.109544_b0400","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-015-3078-6","article-title":"(68)Ga-PSMA PET\/CT for restaging recurrent prostate cancer: which factors are associated with PET\/CT detection rate?","volume":"42","author":"Ceci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2023.109544_b0405","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2023.109544_b0410","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2023.109544_b0415","doi-asserted-by":"crossref","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208-16. Epub 2020\/03\/27. doi: 10.1016\/s0140-6736(20)30314-7. PubMed PMID: 32209449.","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"10.1016\/j.radonc.2023.109544_b0420","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome after PSMA PET\/CT\u2013based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a 2-institution retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2023.109544_b0425","doi-asserted-by":"crossref","unstructured":"Janssen J, Staal FHE, Brouwer CL, Langendijk JA, de Jong IJ, van Moorselaar RJA, et al. Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial. BMC Cancer. 2022;22:482. Epub 20220502. doi: 10.1186\/s12885-022-09523-2. PubMed PMID: 35501744; PubMed Central PMCID: PMC9063099.","DOI":"10.1186\/s12885-022-09523-2"},{"key":"10.1016\/j.radonc.2023.109544_b0430","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: II. the effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch Surg"},{"key":"10.1016\/j.radonc.2023.109544_b0435","doi-asserted-by":"crossref","unstructured":"Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer discovery. 2013;3:1254-71. Epub 2013\/09\/11. doi: 10.1158\/2159-8290.CD-13-0108. PubMed PMID: 24027197.","DOI":"10.1158\/2159-8290.CD-13-0108"},{"key":"10.1016\/j.radonc.2023.109544_b0440","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.radonc.2023.109544_b0445","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-07-0561","article-title":"Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response","volume":"67","author":"Milosevic","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2023.109544_b0450","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-11-2711","article-title":"Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer","volume":"18","author":"Milosevic","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.109544_b0455","doi-asserted-by":"crossref","unstructured":"Mainta IC, Zilli T, Tille JC, De Perrot T, Vall\u00e9e JP, Buchegger F, et al. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An. Int J Radiat Oncol Biol Phys. 2018;102:1210-8. Epub 20180308. doi: 10.1016\/j.ijrobp.2018.02.170. PubMed PMID: 29678527.","DOI":"10.1016\/j.ijrobp.2018.02.170"},{"key":"10.1016\/j.radonc.2023.109544_b0460","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/j.1939-4640.1992.tb00337.x","article-title":"Androgen regulation of programmed death of normal and malignant prostatic cells","volume":"13","author":"Isaacs","year":"1992","journal-title":"J Androl"},{"key":"10.1016\/j.radonc.2023.109544_b0465","doi-asserted-by":"crossref","unstructured":"Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:9887-92. Epub 2014\/06\/23. doi: 10.1073\/pnas.1402468111. PubMed PMID: 24958858.","DOI":"10.1073\/pnas.1402468111"},{"key":"10.1016\/j.radonc.2023.109544_b0470","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.4049\/jimmunol.173.10.6098","article-title":"Augmentation of T cell levels and responses induced by androgen deprivation","volume":"173","author":"Roden","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2023.109544_b0475","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri2817","article-title":"Prostate cancer as a model for tumour immunotherapy","volume":"10","author":"Drake","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.radonc.2023.109544_b0480","doi-asserted-by":"crossref","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine. 2016;375:1415-24. doi: doi:10.1056\/NEJMoa1606220. PubMed PMID: 27626136.","DOI":"10.1056\/NEJMoa1606220"},{"key":"10.1016\/j.radonc.2023.109544_b0485","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/cncr.30049","article-title":"Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer","volume":"122","author":"Falchook","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.109544_b0490","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2010.04.004","article-title":"Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer","volume":"80","author":"Krauss","year":"2011","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.109544_b0495","doi-asserted-by":"crossref","unstructured":"Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, et al. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. Journal of Clinical Oncology. 2020:JCO.19.03217. doi: 10.1200\/JCO.19.03217","DOI":"10.1200\/JCO.19.03217"},{"key":"10.1016\/j.radonc.2023.109544_b0500","doi-asserted-by":"crossref","unstructured":"Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106-14. Epub 20220422. doi: 10.1016\/j.eururo.2022.04.003. PubMed PMID: 35469702.","DOI":"10.1016\/j.eururo.2022.05.034"},{"key":"10.1016\/j.radonc.2023.109544_b0505","doi-asserted-by":"crossref","unstructured":"Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, et al. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022;8:e216871. Epub 20220317. doi: 10.1001\/jamaoncol.2021.6871. PubMed PMID: 35050303; PubMed Central PMCID: PMC8778608","DOI":"10.1001\/jamaoncol.2021.6871"},{"key":"10.1016\/j.radonc.2023.109544_b0510","doi-asserted-by":"crossref","unstructured":"Moore A, Stav I, Den RB, Gordon N, Sarfaty M, Neiman V, et al. The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. J Oncol. 2019;2019:8170428. Epub 2019\/02\/06. doi: 10.1155\/2019\/8170428. PubMed PMID: 30719039; PubMed Central PMCID: PMC6334370.","DOI":"10.1155\/2019\/8170428"},{"key":"10.1016\/j.radonc.2023.109544_b0515","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85\u201331","volume":"23","author":"Lawton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0520","doi-asserted-by":"crossref","unstructured":"Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572-8. doi: 10.1016\/S0140-6736(05)67101-2. PubMed PMID: 16099293.","DOI":"10.1016\/S0140-6736(05)67101-2"},{"key":"10.1016\/j.radonc.2023.109544_b0525","doi-asserted-by":"crossref","unstructured":"Spohn SKB, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, et al. Genomic classifiers in personalized prostate cancer radiotherapy approaches - a systematic review and future perspectives based on international consensus. Int J Radiat Oncol Biol Phys. 2022. Epub 20221231. doi: 10.1016\/j.ijrobp.2022.12.038. PubMed PMID: 36596346.","DOI":"10.1016\/j.ijrobp.2022.12.038"},{"key":"10.1016\/j.radonc.2023.109544_b0530","doi-asserted-by":"crossref","unstructured":"Jairath NK, Dal Pra A, Vince R, Dess RT, Jackson WC, Tosoian JJ, et al. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2021;79:374-83. Epub 20201205. doi: 10.1016\/j.eururo.2020.11.021. PubMed PMID: 33293078.","DOI":"10.1016\/j.eururo.2020.11.021"},{"key":"10.1016\/j.radonc.2023.109544_b0535","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109544_b0540","doi-asserted-by":"crossref","unstructured":"Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of (68)Ga-PSMA-11 PET\/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC cancer. 2019;19:18-. doi: 10.1186\/s12885-018-5200-1. PubMed PMID: 30616601.","DOI":"10.1186\/s12885-018-5200-1"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:53Z","timestamp":1759123553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":108,"alternative-id":["S0167814023000828"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109544","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109544"}}